Clinical-Stage Biotech Aktis Oncology (AKTS.US) Files for $100M IPO to Advance Solid Tumor Therapies

Stock News12-22 16:12

Clinical-stage biopharmaceutical company Aktis Oncology (AKTS.US), specializing in targeted alpha-particle radiopharmaceuticals for solid tumors, filed with the SEC last Friday for an initial public offering seeking up to $100 million.

The Massachusetts-based firm focuses on developing radiopharmaceuticals against prevalent solid tumors. Its lead candidate, Ac-AKY-1189, targets Nectin-4 expressing cancers and is currently in multicenter Phase Ib trials in the U.S. with approximately 150 patients enrolled. Preliminary clinical data is expected in Q1 2027. Another pipeline asset, Ac-AKY-2519 targeting B7-H3 expressing tumors, plans to submit an IND application in 2026.

Aktis has established isotope supply partnerships with multiple institutions and expects its cGMP-compliant manufacturing facility to become operational in 2026. The company is also expanding its radioconjugate drug pipeline through collaborative research programs.

Founded in 2020 and headquartered in Boston, Aktis reported $6 million revenue for the 12 months ending September 30, 2025. The company plans to list on Nasdaq under the ticker "AKTS" with J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen serving as joint bookrunners. Pricing terms have not yet been disclosed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128198762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 16:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128198762","market":"nz","top_or_hot":-1,"title":"Clinical-Stage Biotech Aktis Oncology (AKTS.US) Files for $100M IPO to Advance Solid Tumor Therapies","media":"Stock News","content":"<p>Clinical-stage biopharmaceutical company Aktis Oncology (AKTS.US), specializing in targeted alpha-particle radiopharmaceuticals for solid tumors, filed with the SEC last Friday for an initial public offering seeking up to $100 million.</p>\n<p>The Massachusetts-based firm focuses on developing radiopharmaceuticals against prevalent solid tumors. Its lead candidate, Ac-AKY-1189, targets Nectin-4 expressing cancers and is currently in multicenter Phase Ib trials in the U.S. with approximately 150 patients enrolled. Preliminary clinical data is expected in Q1 2027. Another pipeline asset, Ac-AKY-2519 targeting B7-H3 expressing tumors, plans to submit an IND application in 2026.</p>\n<p>Aktis has established isotope supply partnerships with multiple institutions and expects its cGMP-compliant manufacturing facility to become operational in 2026. The company is also expanding its radioconjugate drug pipeline through collaborative research programs.</p>\n<p>Founded in 2020 and headquartered in Boston, Aktis reported $6 million revenue for the 12 months ending September 30, 2025. The company plans to list on Nasdaq under the ticker \"AKTS\" with J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen serving as joint bookrunners. Pricing terms have not yet been disclosed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinical-Stage Biotech Aktis Oncology (AKTS.US) Files for $100M IPO to Advance Solid Tumor Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinical-Stage Biotech Aktis Oncology (AKTS.US) Files for $100M IPO to Advance Solid Tumor Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-22 16:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clinical-stage biopharmaceutical company Aktis Oncology (AKTS.US), specializing in targeted alpha-particle radiopharmaceuticals for solid tumors, filed with the SEC last Friday for an initial public offering seeking up to $100 million.</p>\n<p>The Massachusetts-based firm focuses on developing radiopharmaceuticals against prevalent solid tumors. Its lead candidate, Ac-AKY-1189, targets Nectin-4 expressing cancers and is currently in multicenter Phase Ib trials in the U.S. with approximately 150 patients enrolled. Preliminary clinical data is expected in Q1 2027. Another pipeline asset, Ac-AKY-2519 targeting B7-H3 expressing tumors, plans to submit an IND application in 2026.</p>\n<p>Aktis has established isotope supply partnerships with multiple institutions and expects its cGMP-compliant manufacturing facility to become operational in 2026. The company is also expanding its radioconjugate drug pipeline through collaborative research programs.</p>\n<p>Founded in 2020 and headquartered in Boston, Aktis reported $6 million revenue for the 12 months ending September 30, 2025. The company plans to list on Nasdaq under the ticker \"AKTS\" with J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen serving as joint bookrunners. Pricing terms have not yet been disclosed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKTS","symbol_name":"Akoustis Technologies Inc","start_time":0,"source_url":"","article_id":"1128198762","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128198762","pubTimestamp":1766391142,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clinical-stage biopharmaceutical company Aktis Oncology (AKTS.US), specializing in targeted alpha-particle radiopharmaceuticals for solid tumors, filed with the SEC last Friday for an initial public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKTS":"Akoustis Technologies Inc","BK4148":"电子元件"},"translate_title":"临床阶段生物技术Aktis Oncology(AKTS.US)申请1亿美元IPO以推进实体瘤疗法","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKTS":1},"content_text":"Clinical-stage biopharmaceutical company Aktis Oncology (AKTS.US), specializing in targeted alpha-particle radiopharmaceuticals for solid tumors, filed with the SEC last Friday for an initial public offering seeking up to $100 million.\nThe Massachusetts-based firm focuses on developing radiopharmaceuticals against prevalent solid tumors. Its lead candidate, Ac-AKY-1189, targets Nectin-4 expressing cancers and is currently in multicenter Phase Ib trials in the U.S. with approximately 150 patients enrolled. Preliminary clinical data is expected in Q1 2027. Another pipeline asset, Ac-AKY-2519 targeting B7-H3 expressing tumors, plans to submit an IND application in 2026.\nAktis has established isotope supply partnerships with multiple institutions and expects its cGMP-compliant manufacturing facility to become operational in 2026. The company is also expanding its radioconjugate drug pipeline through collaborative research programs.\nFounded in 2020 and headquartered in Boston, Aktis reported $6 million revenue for the 12 months ending September 30, 2025. The company plans to list on Nasdaq under the ticker \"AKTS\" with J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen serving as joint bookrunners. Pricing terms have not yet been disclosed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128198762","isCrawlerRequest":true}